SAB Biotherapeutics
SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin for type 1 diabetes and other autoimmune diseases.
- 64
- Company
- Miami Beach, FL, USUnited States
SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin for type 1 diabetes and other autoimmune diseases.
sab.bioCrawled Oct 15, 2026
SAB BIO addresses unmet needs in autoimmune and immune disorders.
The page lists corporate headquarters at 777 W 41st St., Suite 401, Miami Beach, FL 33140, and a Research & Development Campus at 2100 East 54th Street North.
The page describes the physical and mental burden of type 1 diabetes on patients and caregivers and the need for treatments that can delay onset or modify disease trajectory.
SAB Biotherapeutics, Inc.'s privacy policy is effective July 1, 2014.
SAB Biotherapeutics announces a conference call and webcast to discuss its third-quarter 2026 financial results. The event is scheduled for November 5, 2026, at 08:30 AM ET. Investors and stakeholders will receive updates on the company’s financial performance and operational progress.
Oct 2026GlobeNewswireNews article
SAB Biotherapeutics secures FDA Fast Track designation for its experimental therapy **SAB-142**, targeting **stage 3 type 1 diabetes**. The designation accelerates clinical development and review for the treatment, which aims to address autoimmune destruction of insulin-producing cells. The company now moves closer to potential regulatory approval for a condition affecting millions globally.
Oct 2026GlobeNewswireNews article
SAB Biotherapeutics presents new data highlighting the distinct characteristics of its experimental therapy **SAB-142** at the **2026 Immunology of Diabetes Society Congress**. The findings aim to underscore the drug’s potential differentiation in diabetes immunotherapy research. The presentation follows ongoing evaluations of SAB-142’s mechanism in modulating immune responses relevant to type 1 diabetes.
Apr 2026GlobeNewswireNews article
SAB Biotherapeutics, Inc. (Nasdaq: SABS) launches an underwritten public offering of common stock and pre-funded warrants. The clinical-stage biopharmaceutical company focuses on developing a fully human anti-thymocyte immunoglobulin (hATG) for treating type 1 diabetes (T1D) and other autoimmune diseases. The offering aims to raise capital for its ongoing research and development efforts.
Mar 2026Yahoo FinanceNews article